A decision on the approval of AstraZeneca and Daiichi Sankyo’s therapy for breast cancer is expected in 2025. Credit: rafapress / Shutterstock.com.

The US Food and Drug Administration (FDA) has accepted AstraZeneca and Daiichi Sankyo‘s biologics licence application (BLA) for datopotamab deruxtecan (Dato-DXd), a new treatment option for a subset of breast cancer patients.

The application sought approval for the use of Dato-DXd in adults with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have undergone previous systemic therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Prescription Drug User Fee Act deadline for the FDA’s decision will be in the first quarter of 2025.

The regulatory milestone is based on the outcomes of the TROPION-Breast01 Phase III clinical trial, which is a global, randomised, multicentre, open-label study designed to assess the efficacy and safety of Dato-DXd against selected single-agent chemotherapies.

Dato-DXd showed an improvement in progression-free survival versus the investigator’s choice of chemotherapy.

See Also:

While interim results for the dual primary endpoint of overall survival indicated a numerical advantage for Dato-DXd over chemotherapy, the findings were not mature at the time of the data cut-off.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dato-DXd’s safety profile was in line with earlier studies.

Datopotamab deruxtecan is a TROP2-directed DXd antibody-drug conjugate initially discovered by Daiichi Sankyo. The asset is being developed in partnership with AstraZeneca under a global agreement signed in July 2020.

Another BLA for Dato-DXd is under review in the US, based on results from the pivotal TROPION-Lung01 Phase III trial for treating adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer post systemic therapy.

AstraZeneca oncology research and development executive vice-president Susan Galbraith stated: “Despite marked progress in the treatment of HR-positive, HER2-negative breast cancer, most patients with advanced disease develop endocrine resistance and face the prospect of one or several lines of chemotherapy.

“If approved, datopotamab deruxtecan has the potential to provide these patients an efficacious and better-tolerated alternative to conventional chemotherapy.”

Last month,  the Japanese Ministry of Health, Labour and Welfare approved AstraZeneca‘s Truqap (capivasertib) plus Faslodex (fulvestrant) for a specific type of breast cancer.